| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $925K | -28.7% | -51.0% |
| SG&A Expense | $1.9M | -7.6% | -22.6% |
| Operating Income | -$2.8M | +15.7% | +34.9% |
| Net Income | -$2.7M | +15.8% | -112.2% |
| EPS (Basic) | -$0.36 | +16.3% | -112.1% |
| EPS (Diluted) | -$0.36 | +16.3% | -112.1% |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $12.3M | -19.4% | -53.7% |
| Current Assets | $13.0M | -16.3% | -53.4% |
| Total Assets | $28.1M | -7.7% | -34.4% |
| Current Liabilities | $2.7M | +5.7% | -40.4% |
| Total Liabilities | $62.7M | +0.2% | -2.8% |
| Stockholders' Equity |
| Line Item | 2025-09-30 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$9.0M | — | — |
| Investing Cash Flow | $0 | — | — |
| Financing Cash Flow | -$45K | — | — |
| -$34.6M |
| -7.7% |
| -59.6% |